Europe Precision Medicine Market byTechnology (Big Data Analytics, Bioinformatics, Gene sequencing, Drug Discovery, Companion Diagnostic, and Others); End-users (Diagnostic tool companies, Healthcare IT/ Big data companies, Pharma & Biotech companies, and Clinical Labs); and for Application (Oncology, CNS,Immunology, Respiratory and Others) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 - 2024
REPORT BRIEF
The main aspect which will prompt the growth of the Europe precision medicine market is the increasing improved patient outcomes by using precision medicine. Moreover, the healthcare institutions in Europe are willing to use genetic testing and analytics technologies, payers willing to reimburse the cost of high-value drugs. Also, the drug companies that focus on developing new personalized therapies, companion diagnostics providers that propels the improvements in information gathering, and genetic analytics services which help interpret the results. Considering all the above factors the market for precision medicines in Europe is expected to propel significantly during the forecast period.
VALUE
The Europe precision medicine market was valued at around USD 33,200.0 million in the year 2014 and it is expected to reach approximately USD 35,000.0 million by 2024. The Europe precision medicine market is expected to grow at aCAGR of over13% between 2017 and 2024.
DRIVERS AND RESTRAINTS
The major factor driving the growth of Europe precision medicine market is the Increasing demand for personalized treatment. A large number of established online forums in the region, which help clinicians collaborate with one another and share information, which will help in the diagnosis and treatment of patients in a better manner.Increasing focus on targeted therapy by reducing trial and error medicine, advancement of technology in understanding human biology disease susceptibility, and a shift in the significance of medicine from reaction to prevention, among others will propel the precision medicines market in near future.
However, several clinical, economic, ethical and regulatory conditions will continue to challenge the growth of this industry in the years to come.
SEGMENTATION
Big data analytics technology segment is accounted for the largest market share in 2017 and expected to dominate the market by the end of forecast period. Healthcare information technology platforms becoming more widely available that securely store and analyze vast amounts of electronic health record data from thousands of patients, providing doctors with new information and insight to help them deliver more personalized care to their patients.
The diagnostic tool companies segment dominates the European precision medicines market by end-users. Use of comprehensive profiling for patients to determine an appropriate treatment is one of the major advantages of precision medicines This includes not just genetics, but family history, diet, exercise, stress level and more. These factors enable a healthcare provider to develop an effective treatment plan that is not based on the average patient, but the individual patient, instead. Considering all the factors the diagnostic tool companies plays a major role in precision medicine market and hence contribute for the largest share.
Considering the applications of precision medicine market, Oncology segment is anticipated to hold the largest market share. In oncology, the genetic information provides the understanding that not only do tumors differ within tumor heterogeneity, but the information clearly shows that each patients individual tumor is an assemblage of inimitable molecular irregularities that will require an equally exclusive personalized therapeutic regimen. This has increased the preference for precision medicine in oncology applications.
Germany contributes to the largest market share of Europe precision medicine market. U.K. is expected to grow at high CAGR for the precision medicine deployments in Europe, due to different kinds of solutions being offered and services being delivered in the country. Moreover, countries such as Spain, France, and Italy have shown tremendous growth in precision medicine solution developments.
INDUSTRY PLAYERS
The report includes detailed profiles of the prominent market players that are trending in the market. The list of the players that are compiled in the report areRoche, QIAGEN N.V., Cepheid, Inc, Johnson Johnson Services, Inc., Illumina, Almac Group, bioMrieux SA, Intel Corporation, GE Healthcare, Novartis, Thermo Fisher Scientific, and much more.
The prominent market players maintain the competitive edge in the global market by making investments in the mergers and acquisitions and by increasing their product portfolio. For instance recently on 8th January 2018, GE Healthcare and pharmaceutical giant Roche announced a partnership to develop and co-market digital clinical decision support solutions. The companies said that they will focus on precision medicine products to accelerate and improve individualized treatments for cancer and critical care patients.
- The report covers forecast and analysis for the precision medicines market on regional and country level.
- The report includes the positive and the negative factors that are influencing the growth of the market.
- Future opportunities about the Europe precision medicines market are discussed in the report.
- The revenue generated by the prominent industry players has been analyzed in the report.
- The market numbers have been calculated using top-down and the bottom-up approaches.
- The precision medicines market has been analyzed using Porters Five Forces Analysis.
- The market is segmented on the basis of technology, End-user, and applications, which in turn bifurcated on the country level as well.
- All the segments have been evaluated based on the present and the future trends.
- The report deals with the in-depth quantitative and qualitative analyses of the roof safety and access system market.
- The report includes the detailed company profiles of the prominent market players.
The main aspect which will prompt the growth of the Europe precision medicine market is the increasing improved patient outcomes by using precision medicine. Moreover, the healthcare institutions in Europe are willing to use genetic testing and analytics technologies, payers willing to reimburse the cost of high-value drugs. Also, the drug companies that focus on developing new personalized therapies, companion diagnostics providers that propels the improvements in information gathering, and genetic analytics services which help interpret the results. Considering all the above factors the market for precision medicines in Europe is expected to propel significantly during the forecast period.
VALUE
The Europe precision medicine market was valued at around USD 33,200.0 million in the year 2014 and it is expected to reach approximately USD 35,000.0 million by 2024. The Europe precision medicine market is expected to grow at aCAGR of over13% between 2017 and 2024.
DRIVERS AND RESTRAINTS
The major factor driving the growth of Europe precision medicine market is the Increasing demand for personalized treatment. A large number of established online forums in the region, which help clinicians collaborate with one another and share information, which will help in the diagnosis and treatment of patients in a better manner.Increasing focus on targeted therapy by reducing trial and error medicine, advancement of technology in understanding human biology disease susceptibility, and a shift in the significance of medicine from reaction to prevention, among others will propel the precision medicines market in near future.
However, several clinical, economic, ethical and regulatory conditions will continue to challenge the growth of this industry in the years to come.
SEGMENTATION
Big data analytics technology segment is accounted for the largest market share in 2017 and expected to dominate the market by the end of forecast period. Healthcare information technology platforms becoming more widely available that securely store and analyze vast amounts of electronic health record data from thousands of patients, providing doctors with new information and insight to help them deliver more personalized care to their patients.
The diagnostic tool companies segment dominates the European precision medicines market by end-users. Use of comprehensive profiling for patients to determine an appropriate treatment is one of the major advantages of precision medicines This includes not just genetics, but family history, diet, exercise, stress level and more. These factors enable a healthcare provider to develop an effective treatment plan that is not based on the average patient, but the individual patient, instead. Considering all the factors the diagnostic tool companies plays a major role in precision medicine market and hence contribute for the largest share.
Considering the applications of precision medicine market, Oncology segment is anticipated to hold the largest market share. In oncology, the genetic information provides the understanding that not only do tumors differ within tumor heterogeneity, but the information clearly shows that each patients individual tumor is an assemblage of inimitable molecular irregularities that will require an equally exclusive personalized therapeutic regimen. This has increased the preference for precision medicine in oncology applications.
Germany contributes to the largest market share of Europe precision medicine market. U.K. is expected to grow at high CAGR for the precision medicine deployments in Europe, due to different kinds of solutions being offered and services being delivered in the country. Moreover, countries such as Spain, France, and Italy have shown tremendous growth in precision medicine solution developments.
INDUSTRY PLAYERS
The report includes detailed profiles of the prominent market players that are trending in the market. The list of the players that are compiled in the report areRoche, QIAGEN N.V., Cepheid, Inc, Johnson Johnson Services, Inc., Illumina, Almac Group, bioMrieux SA, Intel Corporation, GE Healthcare, Novartis, Thermo Fisher Scientific, and much more.
The prominent market players maintain the competitive edge in the global market by making investments in the mergers and acquisitions and by increasing their product portfolio. For instance recently on 8th January 2018, GE Healthcare and pharmaceutical giant Roche announced a partnership to develop and co-market digital clinical decision support solutions. The companies said that they will focus on precision medicine products to accelerate and improve individualized treatments for cancer and critical care patients.
CHAPTER 1. INTRODUCTION
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Europe Precision Medicines market, 2014 - 2024 (USD Million)
2.2. Europe Precision Medicines market: Snapshot
CHAPTER 3. EUROPE PRECISION MEDICINES - MARKET DYNAMICS
3.1. Introduction
3.2. Market drivers
3.2.1. Increasing Technological advancement
3.3. Market Restraints
3.3.1. The high cost of treatment
3.4. Opportunities
3.4.1. Rising incidence of chronic diseases and growing outbreaks of epidemics
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. The threat of new entrants
3.5.4. The threat of new substitutes
3.5.5. Degree of competition
3.6. Market attractiveness analysis
3.6.1. Market attractiveness analysis, by technology segment
3.6.2. Market attractiveness analysis, by End-users segment
3.6.3. Market attractiveness analysis, by application segment
3.6.4. Market attractiveness analysis, by regional segment
CHAPTER 4. EUROPE PRECISION MEDICINES MARKET- COMPETITIVE LANDSCAPE
4.1. Company Market Share Analysis
4.1.1. Europe Precision Medicines market: company market share, 2014
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Therapy Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development, Therapy and Regional Expansion
CHAPTER 5. EUROPE PRECISION MEDICINES MARKET- TECHNOLOGY SEGMENT ANALYSIS
5.1. Europe Precision Medicines market: Technology type overview
5.1.1. Europe Precision Medicines market revenue share, by technology, 2014 and 2024
5.2. Big Data Analytics
5.2.1. Europe Big Data Analytics market, 2014 - 2024(USD Million)
5.3. Bioinformatics
5.3.1. EuropeBioinformatics market, 2014 - 2024(USD Million)
5.4. Gene sequencing
5.4.1. Europe Gene sequencing market, 2014 - 2024(USD Million)
5.5. Drug Discovery
5.5.1. Europe Drug Discovery market, 2014 - 2024(USD Million)
5.6. Companion Diagnostic
5.6.1. Europe Companion Diagnostic market, 2014 - 2024(USD Million)
5.7. Others
5.7.1. Europe Others market , 2014 - 2024(USD Million)
CHAPTER 6. EUROPE PRECISION MEDICINES MARKET- END-USER SEGMENT ANALYSIS
6.1. Europe Precision Medicines market: End-user overview
6.1.1. Europe Precision Medicines market revenue share, by End-user, 2014- 2024
6.2. Diagnostic tool companies
6.2.1. Europe Precision Medicines market for Diagnostic tool companies, 2014 - 2024 (USD Million)
6.3. Healthcare IT/Big data companies
6.3.1. Europe Precision Medicines market for Healthcare IT/Big data companies,2014 - 2024 (USD Million)
6.4. Pharma Biotech companies
6.4.1. Europe Precision Medicines market for Pharma Biotech companies, 2014 - 2024 (USD Million)
6.5. Clinical Labs
6.5.1. Europe Precision Medicines market for Clinical Labs, 2014 - 2024 (USD Million)
CHAPTER 7. EUROPE PRECISION MEDICINES MARKET- APPLICATION SEGMENT ANALYSIS
7.1. Europe Precision Medicines market: Application overview
7.1.1. Europe Precision Medicines market revenue share, by Application, 2014- 2024
7.2. Oncology
7.2.1. Europe Precision Medicines market for Oncology Application, 2014 - 2024 (USD Million)
7.3. CNS
7.3.1. Europe Precision Medicines market for CNS Application,2014 - 2024 (USD Million)
7.4. Immunology
7.4.1. Europe Precision Medicines market for Immunology Application, 2014 - 2024 (USD Million)
7.5. Respiratory
7.5.1. Europe Precision Medicines market for Respiratory Application, 2014 - 2024 (USD Million)
7.6. Others
7.6.1. Europe Precision Medicines market for Others Application, 2014 - 2024 (USD Million)
CHAPTER 8. EUROPE PRECISION MEDICINES MARKET- REGIONAL SEGMENT ANALYSIS
8.1. Europe Precision Medicines market: Regional overview
8.1.1. Europe Precision Medicines market revenue share, by region, 2014 and 2024
8.2. Germany
8.2.1. Germanyprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.2.2. Germanyprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.2.3. Germanyprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.3. U.K
8.3.1. U.Kprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.3.2. U.Kprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.3.3. U.Kprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.4. France
8.4.1. Franceprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.4.2. Franceprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.4.3. Franceprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.5. Italy
8.5.1. Italyprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.5.2. Italyprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.5.3. Italyprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.6. Spain
8.6.1. Spainprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.6.2. Spainprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.6.3. Spainprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.7. Benelux
8.7.1. Beneluxprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.7.2. Beneluxprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.7.3. Beneluxprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
CHAPTER 9. COMPANY PROFILE
9.1. Roche
9.1.1. Overview
9.1.2. Financials
9.1.3. Therapy portfolio
9.1.4. Business strategy
9.1.5. Recent developments
9.2. QIAGEN N.V.
9.2.1. Overview
9.2.2. Financials
9.2.3. Therapy portfolio
9.2.4. Business strategy
9.2.5. Recent developments
9.3. Cepheid, Inc
9.3.1. Overview
9.3.2. Financials
9.3.3. Therapy portfolio
9.3.4. Business strategy
9.3.5. Recent developments
9.4. Johnson Johnson Services, Inc.
9.4.1. Overview
9.4.2. Financials
9.4.3. Therapy portfolio
9.4.4. Business strategy
9.4.5. Recent developments
9.5. Illumina
9.5.1. Overview
9.5.2. Financials
9.5.3. Therapy portfolio
9.5.4. Business strategy
9.5.5. Recent developments
9.6. Almac Group
9.6.1. Overview
9.6.2. Financials
9.6.3. Therapy portfolio
9.6.4. Business strategy
9.6.5. Recent developments
9.7. bioMrieux SA
9.7.1. Overview
9.7.2. Financials
9.7.3. Therapy portfolio
9.7.4. Business strategy
9.7.5. Recent developments
9.8. Intel Corporation
9.8.1. Overview
9.8.2. Financials
9.8.3. Therapy portfolio
9.8.4. Business strategy
9.8.5. Recent developments
9.9. GE Healthcare
9.9.1. Overview
9.9.2. Financials
9.9.3. Therapy portfolio
9.9.4. Business strategy
9.9.5. Recent developments
9.10. Novartis
9.10.1. Overview
9.10.2. Financials
9.10.3. Therapy portfolio
9.10.4. Business strategy
9.10.5. Recent developments
9.11. Thermo Fisher Scientific
9.11.1. Overview
9.11.2. Financials
9.11.3. Therapy portfolio
9.11.4. Business strategy
9.11.5. Recent developments
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Europe Precision Medicines market, 2014 - 2024 (USD Million)
2.2. Europe Precision Medicines market: Snapshot
CHAPTER 3. EUROPE PRECISION MEDICINES - MARKET DYNAMICS
3.1. Introduction
3.2. Market drivers
3.2.1. Increasing Technological advancement
3.3. Market Restraints
3.3.1. The high cost of treatment
3.4. Opportunities
3.4.1. Rising incidence of chronic diseases and growing outbreaks of epidemics
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. The threat of new entrants
3.5.4. The threat of new substitutes
3.5.5. Degree of competition
3.6. Market attractiveness analysis
3.6.1. Market attractiveness analysis, by technology segment
3.6.2. Market attractiveness analysis, by End-users segment
3.6.3. Market attractiveness analysis, by application segment
3.6.4. Market attractiveness analysis, by regional segment
CHAPTER 4. EUROPE PRECISION MEDICINES MARKET- COMPETITIVE LANDSCAPE
4.1. Company Market Share Analysis
4.1.1. Europe Precision Medicines market: company market share, 2014
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Therapy Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development, Therapy and Regional Expansion
CHAPTER 5. EUROPE PRECISION MEDICINES MARKET- TECHNOLOGY SEGMENT ANALYSIS
5.1. Europe Precision Medicines market: Technology type overview
5.1.1. Europe Precision Medicines market revenue share, by technology, 2014 and 2024
5.2. Big Data Analytics
5.2.1. Europe Big Data Analytics market, 2014 - 2024(USD Million)
5.3. Bioinformatics
5.3.1. EuropeBioinformatics market, 2014 - 2024(USD Million)
5.4. Gene sequencing
5.4.1. Europe Gene sequencing market, 2014 - 2024(USD Million)
5.5. Drug Discovery
5.5.1. Europe Drug Discovery market, 2014 - 2024(USD Million)
5.6. Companion Diagnostic
5.6.1. Europe Companion Diagnostic market, 2014 - 2024(USD Million)
5.7. Others
5.7.1. Europe Others market , 2014 - 2024(USD Million)
CHAPTER 6. EUROPE PRECISION MEDICINES MARKET- END-USER SEGMENT ANALYSIS
6.1. Europe Precision Medicines market: End-user overview
6.1.1. Europe Precision Medicines market revenue share, by End-user, 2014- 2024
6.2. Diagnostic tool companies
6.2.1. Europe Precision Medicines market for Diagnostic tool companies, 2014 - 2024 (USD Million)
6.3. Healthcare IT/Big data companies
6.3.1. Europe Precision Medicines market for Healthcare IT/Big data companies,2014 - 2024 (USD Million)
6.4. Pharma Biotech companies
6.4.1. Europe Precision Medicines market for Pharma Biotech companies, 2014 - 2024 (USD Million)
6.5. Clinical Labs
6.5.1. Europe Precision Medicines market for Clinical Labs, 2014 - 2024 (USD Million)
CHAPTER 7. EUROPE PRECISION MEDICINES MARKET- APPLICATION SEGMENT ANALYSIS
7.1. Europe Precision Medicines market: Application overview
7.1.1. Europe Precision Medicines market revenue share, by Application, 2014- 2024
7.2. Oncology
7.2.1. Europe Precision Medicines market for Oncology Application, 2014 - 2024 (USD Million)
7.3. CNS
7.3.1. Europe Precision Medicines market for CNS Application,2014 - 2024 (USD Million)
7.4. Immunology
7.4.1. Europe Precision Medicines market for Immunology Application, 2014 - 2024 (USD Million)
7.5. Respiratory
7.5.1. Europe Precision Medicines market for Respiratory Application, 2014 - 2024 (USD Million)
7.6. Others
7.6.1. Europe Precision Medicines market for Others Application, 2014 - 2024 (USD Million)
CHAPTER 8. EUROPE PRECISION MEDICINES MARKET- REGIONAL SEGMENT ANALYSIS
8.1. Europe Precision Medicines market: Regional overview
8.1.1. Europe Precision Medicines market revenue share, by region, 2014 and 2024
8.2. Germany
8.2.1. Germanyprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.2.2. Germanyprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.2.3. Germanyprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.3. U.K
8.3.1. U.Kprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.3.2. U.Kprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.3.3. U.Kprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.4. France
8.4.1. Franceprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.4.2. Franceprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.4.3. Franceprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.5. Italy
8.5.1. Italyprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.5.2. Italyprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.5.3. Italyprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.6. Spain
8.6.1. Spainprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.6.2. Spainprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.6.3. Spainprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
8.7. Benelux
8.7.1. Beneluxprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)
8.7.2. Beneluxprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)
8.7.3. Beneluxprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)
CHAPTER 9. COMPANY PROFILE
9.1. Roche
9.1.1. Overview
9.1.2. Financials
9.1.3. Therapy portfolio
9.1.4. Business strategy
9.1.5. Recent developments
9.2. QIAGEN N.V.
9.2.1. Overview
9.2.2. Financials
9.2.3. Therapy portfolio
9.2.4. Business strategy
9.2.5. Recent developments
9.3. Cepheid, Inc
9.3.1. Overview
9.3.2. Financials
9.3.3. Therapy portfolio
9.3.4. Business strategy
9.3.5. Recent developments
9.4. Johnson Johnson Services, Inc.
9.4.1. Overview
9.4.2. Financials
9.4.3. Therapy portfolio
9.4.4. Business strategy
9.4.5. Recent developments
9.5. Illumina
9.5.1. Overview
9.5.2. Financials
9.5.3. Therapy portfolio
9.5.4. Business strategy
9.5.5. Recent developments
9.6. Almac Group
9.6.1. Overview
9.6.2. Financials
9.6.3. Therapy portfolio
9.6.4. Business strategy
9.6.5. Recent developments
9.7. bioMrieux SA
9.7.1. Overview
9.7.2. Financials
9.7.3. Therapy portfolio
9.7.4. Business strategy
9.7.5. Recent developments
9.8. Intel Corporation
9.8.1. Overview
9.8.2. Financials
9.8.3. Therapy portfolio
9.8.4. Business strategy
9.8.5. Recent developments
9.9. GE Healthcare
9.9.1. Overview
9.9.2. Financials
9.9.3. Therapy portfolio
9.9.4. Business strategy
9.9.5. Recent developments
9.10. Novartis
9.10.1. Overview
9.10.2. Financials
9.10.3. Therapy portfolio
9.10.4. Business strategy
9.10.5. Recent developments
9.11. Thermo Fisher Scientific
9.11.1. Overview
9.11.2. Financials
9.11.3. Therapy portfolio
9.11.4. Business strategy
9.11.5. Recent developments
